Distinct Clinical and Prognostic Features of Acute and Chronic Active Epstein–Barr Virus-Associated Hemophagocytic Lymphohistiocytosis in Adults: A Scoping Review Authors: Tiankuo Gao, Chun Yang, Yingxin Zhu, Junling Hu, Chen Gong, Yini Wang, Yue Song Published: 2026 ABSTRACT AbstractEpstein–Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) is a major subtype of secondary HLH and is increasingly recognized as a heterogeneous entity. However, the clinical differences between acute EBV-HLH (AEBV-HLH) and chronic active EBV infection-associated HLH (CAEBV-HLH) have not been systematically characterized. We conducted a scoping review of PubMed up to December 7, 2024, and identified 168 eligible articles involving 714 adult patients with EBV-HLH, including 584 with AEBV-HLH and 130 with CAEBV-HLH. Epidemiologic features, clinical manifestations, treatment patterns, and prognostic factors were summarized and compared between the two subgroups. Patients with AEBV-HLH showed more severe HLH-related abnormalities, including lower blood counts and higher ferritin, triglyceride, lactate dehydrogenase, and plasma EBV-DNA levels, whereas central nervous system involvement was more frequent in CAEBV-HLH. The median overall survival was significantly longer in CAEBV-HLH (8.9 months) than AEBV-HLH (2.4 months, P=0.005). In the overall cohort, ferritin >5000 μg/L, soluble CD25 >10000 U/mL, EBV-DNA >10000 copies/mL, and receiving hematopoietic stem cell transplantation (HSCT) were independently associated with better overall survival. In subgroup analyses, soluble CD25, EBV-DNA, and HSCT remained independent predictors in AEBV-HLH, whereas undergoing HSCT was the only independent prognostic factor in CAEBV-HLH. These findings support distinct clinical and prognostic characteristics between AEBV-HLH and CAEBV-HLH, especially in adults. AEBV-HLH is characterized by a more fulminant inflammatory presentation, whereas CAEBV-HLH more often follows a chronic course with greater extensive organ. HSCT appears to be central to long-term outcome in both subtypes. Introduction Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening inflammatory syndrome characterized by dysfunction of cytotoxic T lymphocytes and natural killer cells, accompanied by overactivation of macrophages, ultimately leading to cytokine storm. Clinical features include persistent fever, decreased peripheral blood cells, enlarged liver and spleen lymph nodes, liver dysfunction, and coagulation dysfunction. Based on etiology, HLH is classified into primary and secondary HLH (sHLH). Epstein–Barr virus-associated HLH (EBV-HLH) is one of the most common subtypes of sHLH, which has remained as a major challenge in the management of HLH.1 The relationship between Epstein–Barr virus (EBV) and HLH is complex and wide-ranging. EBV-HLH has been increasingly recognized as a heterogeneous clinical entity rather than a single disease category, especially in adult patients.2,3 Diagnosis in adults is challenging due to its rarity and overlap with malignant lymphomas, leading to delayed diagnosis and a poor prognosis. Although patients share the common syndrome of hyperinflammation and HLH triggered by EBV infection, the underlying disease context may differ substantially. In some patients, HLH develops in the setting of acute EBV infection (AEBV-HLH), typically infecting B-cells, with polyclonal immune activation with fulminant inflammation.4 In others, HLH arises on the background of chronic active Epstein–Barr virus infection (CAEBV-HLH), which is characterized by persistent clonal proliferation of EBV infected T/NK cells, sustained immune dysregulation, and a recurrent disease course.5 These background differences suggest that AEBV-HLH and CAEBV-HLH may represent biologically and clinically distinct subgroups within EBV-HLH. At present, there is no standardized therapeutic strategy for adult patients with EBV-HLH. The widely adopted HLH‑1994 and HLH-2004 (HLH-94/04) regimen mainly targets excessive immune activation and inflammation, yet often fails to achieve sustained control of EBV infection.6 Hematopoietic stem cell transplantation (HSCT) represents the potentially curative approach for pediatric with refractory/relapsed EBV-HLH,7 and also improves the overall survival (OS) of adult EBV-HLH significantly.2 However, the role of HSCT in adult patients with CAEBV-HLH and AEBV-HLH respectively remains unclear. However, current studies have often grouped AEBV-HLH and CAEBV-HLH together, which may obscure differences in disease course, treatment response, and prognosis and limit the precision of clinical decision-making. Moreover, adult EBV-HLH is rare, and the lack of large multicenter studies limits the current evidence base. Although EBV-HLH is particularly prevalent in East Asian populations, available evidence remains geographically limited. To address this gap, we conducted a scoping review to synthesize the available evidence on adult EBV-HLH, summarize its epidemiology, clinical manifestations, treatment strategies, and prognostic factors, and highlight the differences between AEBV-HLH and CAEBV-HLH. Method Search Strategy Under the PRISMA guidelines,8 a comprehensive literature search of PubMed was performed, covering the period from database establishment to 7 December 2024. The search terms were shown in Supplementary File. Data Extraction Two investigators independently extracted individual patient data from the full text, tables, figures, and supplementary materials of the included studies. Extracted information included patient characteristics, laboratory indices, treatment regimens, and clinical outcomes. When necessary, the authors were contacted to request additional information for missing or ambiguous data. Study Eligibility Criteria The inclusion and exclusion criteria were applied at the study level, not the patient level. Inclusion criteria were as follows: (1) Studies reporting adult patients (≥18 years) diagnosed with HLH according to the HLH-2004 criteria or with a confirmed HLH diagnosis by authors of the original study. (2) English-language articles. (3) For overlapping cohorts, only the most recent publication was retained. Exclusion criteria were as follows: (1) Studies with incomplete or insufficient individual patient data. (2) Cases in which HLH was triggered by non-EBV causes, including genetic mutations, autoimmune diseases, or malignancies. (3) EBV-associated lymphoma-HLH. (4) Non-English-language articles. HLH was diagnosed in accordance with the HLH-2004 diagnostic criteria.9 EBV-HLH was defined by evidence of EBV infection, which was determined based on an EBV DNA load of ≥500 copies in plasma or peripheral blood mononuclear cells, as well as positive EBV-encoded RNA (EBER) detected by in situ hybridization in tissues. According to the duration of HLH symptoms, EBV-HLH was classified into CAEBV-HLH and AEBV-HLH. CAEBV was diagnosed based on persistent or recurrent IM-like symptoms for more than 3 months, markedly increased EBV DNA load in peripheral blood or tissues, and exclusion of primary immunodeficiency and other lymphoproliferative disorders.10 CAEBV-HLH was defined as CAEBV progressing to HLH, concurrent fulfilled the diagnostic criteria for CAEBV and HLH. AEBV-HLH was defined as HLH with acute EBV infection lasting less than 3 months. EBV associated lymphoma-HLH was excluded from this research. The survival times mentioned in the analyzed articles were extracted and recorded in months. Statistical Methods R software version 4.3.1 and SPSS software version 23.0 were used for statistical analyses in our study. Continuous variables were presented as median (interquartile range, IQR), because the distributions were non-normal. Categorical variables were summarized as frequency (percentage). Comparisons between groups were performed using the Mann–Whitney U-test regarding continuous variables and Chi-Square test for categorical variables. Kaplan–Meier survival curves were used to evaluate OS, and Log rank tests were performed for comparison of subgroups. A time-dependent Cox regression model was used to evaluate the association between patient characteristics including HLH and EBV related laboratory parameters and OS. The cut-off values of clinical and laboratory indicators listed in COX regression model were adopted from survival-associated thresholds reported in previous studies focusing on HLH patients, and routine clinical normal reference ranges. Variables with a p < 0.05 in univariate analysis were included in multivariate analysis with a bidirectional stepwise selection procedure to analyze the independent prognostic factors for OS. Result Literature Search Initially, titles and abstracts of all 1451 PubMed results were evaluated according to inclusion and exclusion criteria. Eleven additional articles were identified through cross-referencing. After screening the titles and abstracts, 1163 articles were excluded from further analysis. The remaining 299 full-text articles were reassessed based on the initial criteria. Finally, 168 articles including 138 case reports and 30 cohort studies met the inclusion criteria (Supplementary File), providing clinical data of 714 EBV-HLH patients (584 of AEBV-HLH and 130 of CAEBV-HLH). The literature search and screening processes are summarized in Figure 1. Supplementary Figure 1 showed the publication output from 1987 to the present. As the understanding and diagnostic awareness of EBV-HLH have increased, the annual number of publications has increased over time. Figure 1Flowchart of literature search and screening.This chart illustrates the number of records identified, screened, excluded, and ultimately included, as well as the reasons for exclusion at each stage. Initially, 1451 reports were identified through database searching, with 11 additional reports found via cross-referencing. Out of these, 1163 reports were excluded for reasons such as other HLH triggers, not being case reports or cohorts, pediatric population issues, non-English articles and lack of full text. This left 299 full-text articles assessed for eligibility. Data of one reportwas provided by the author. Subsequently, 131 reports were excluded for reasons. Ultimately, 168 studies were included for analysis.A flowchart of literature search and screening process for study inclusion.Abbreviations: HLH, hemophagocytic lymphohistiocytosis; EBV-HLH, Epstein–Barr virus-associated HLH. Flowchart of literature search and screening. The geographical distribution of patients, based on the number of patients, is shown in Supplementary Figure 2. The majority of patients come from Asia (89.2%), followed by the Americas and Europe (6.6% and 4.0%, respectively). Specifically, the number of patients from China is the largest (496 patients, with one study including detailed patient data for 356 cases), followed by Japan, South Korea, and the United States (75, 53, and 44 patients, respectively). Baseline Clinical Features For all EBV-HLH patients, baseline characteristics revealed a male predominance (62.0%), with a median age of 31 years. Fever was present in nearly all cases (99.0%). Forty-four point one percent of patients exhibited hepatomegaly, whereas splenomegaly had a higher prevalence (81.8%). Approximately half of the patients (52.6%) presented with lymphadenopathy. Peripheral blood cytopenia was observed: thrombocytopenia (77.3%) and leukopenia (74.7%) were observed frequently, followed by anemia (49.6%) and neutropenia (43.3%). Elevated triglycerides were observed in 42% of the patients, while low fibrinogen was present in 48%. About 90% patients had elevated soluble CD25 (sCD25) levels, with a median of 19868 U/mL for the entire cohort. Hemophagocytosis in bone marrow (BM) was found in 78.3% patients. For AEBV-HLH and CAEBV-HLH subgroup comparison, central nervous system involvement demonstrated significantly higher frequency in CAEBV-HLH patients compared to AEBV-HLH (P=0.017). AEBV group showed lower white blood cell and platelets count than CAEBV-HLH patients (p=0.021). Elevated triglycerides were observed only in AEBV group (P=0.034). Lactate dehydrogenase (LDH) (P=0.015), ferritin (P=0.001) and triglyceride (P=0.017) were higher in the AEBV group than in CAEBV group. EBV-DNA loads in plasma were higher in the AEBV group than in CAEBV-HLH group (P=0.045). The clinical characteristics of enrolled patients are summarized in Supplementary Table 1. Treatment Characteristics Treatment information was available for 523 patients in the entire cohort, 410 in AEBV group and 113 in CAEBV group, respectively. Overall, most patients received combination therapy, with corticosteroids and etoposide being the most commonly used agents. Protocol-based regimens, including DEP/L-DEP and HLH-94/04, were also frequently administered, and nearly one-third (28.9%, 151/523) of patients ultimately underwent HSCT. For subgroups, AEBV-HLH patients were more likely to receive corticosteroid monotherapy than CAEBV-HLH (8.5% vs 1.8%, P = 0.023), as well as cyclophosphamide (7.8% vs 0, P = 0.005) and cyclosporine A (34.6% vs 23.9%, P = 0.041). In contrast, patients with CAEBV-HLH were more to receive corticosteroids as part of combination therapy (88.5% vs 78.8%, P = 0.029) and to proceed to HSCT (38.9% vs 26.1%, P = 0.011). Detailed treatment information is shown in Supplementary Table 2. Prognostic Factors and Outcome Information on outcome and corresponding follow-up times was available for 546 patients in the entire cohort, including 428 AEBV-HLH and 118 CAEBV-HLH, with an estimated median survival time (MST) of 4.6 months (95% CI, 3.8–5.4) (Figure 2A). Compared with AEBV group, patients with CAEBV-HLH had better OS (median survival 8.9 vs 2.4 months, P=0.005, Figure 2B). MST in patients who received HSCT was 10.9 months, longer than patients without HSCT (3.3 months, P=0.005, Figure 3A). In both AEBV (P<0.001, Figure 3B) and CAEBV (P<0.001, Figure 3C) group, HSCT significantly improved OS. Compared with HLH-94/04, patients with DEP/LDEP regimen have longer MST (4.7 vs 2.7 months, P=0.007, Figure 3D). DEP/LDEP regimen provided a 30-day OS rate of 95.1%, notably higher than HLH-94/04 group (85.3%, P<0.001). Further analysis shows that among patients received HSCT, patients with DEP/LDEP regimen had better survival than those with HLH-94/04 regimen (MST 10.5 vs 5.0 months, P=0.029). However, among the non-HSCT patients, there was no difference in OS between DEP/LDEP group and HLH-94/04 group (MST 3.8 vs 3.4 months, P=0.270), suggesting that the DEP/L-DEP regimen appeared to function primarily as a bridging regimen to HSCT rather than a curative therapy. Figure 2Kaplan-Meier survival curves of (A) entire cohort and (B) AEBV-HLH vs CAEBV-HLH group.Panel A shows the Kaplan-Meier survival curve for the entire cohort. Survival decreases rapidly early on and then declines more gradually over time, reaching about 0.27 at 36 months. Panel B compares AEBV-HLH and CAEBV-HLH. CAEBV-HLH shows better survival than AEBV-HLH, with a significant difference between the two groups (p equals 0.005). At 36 months, survival is approximately 0.33 in the CAEBV-HLH group and 0.25 in the AEBV-HLH group.Kaplan-Meier survival curves showing overall survival in the entire cohort and a comparison between AEBV-HLH and CAEBV-HLH groups.Abbreviations: AEBV-HLH, acute EBV-associated hemophagocytic lymphohistiocytosis; CAEBV-HLH, chronic active EBV-associated hemophagocytic lymphohistiocytosis. Figure 3Kaplan-Meier survival curves. (A) OS of non-SCT and SCT patients. (B) OS of non-SCT and SCT patients in AEBV-HLH group. (C) OS of non-SCT and SCT patients in CAEBV-HLH group. (D) OS of HLH-94/04 and DEP/LDEP regimen.Panel A shows OS in the full cohort, with SCT associated with better survival than non-SCT (p equals 0.005). Panel B shows the same comparison in the AEBV-HLH group, where SCT also performs better than non-SCT (p less than 0.001). Panel C shows the CAEBV-HLH group, with a clear survival advantage for SCT over non-SCT (p less than 0.001). Panel D compares HLH-94/04 and DEP/LDEP regimens, showing better survival with DEP/LDEP (p equals 0.007).Four Kaplan-Meier survival curves comparing non-SCT versus SCT in the overall cohort, AEBV-HLH, and CAEBV-HLH groups, and comparing HLH-94/04 versus DEP/LDEP regimens.Abbreviations: OS, overall survival; AEBV-HLH, acute EBV-associated hemophagocytic lymphohistiocytosis; CAEBV-HLH, chronic active EBV-associated hemophagocytic lymphohistiocytosis; SCT, stem cell transplantation; DEP/L-DEP, liposome doxorubicin, etoposide, methylprednisolone with or without asparaginase. Kaplan-Meier survival curves of (A) entire cohort and (B) AEBV-HLH vs CAEBV-HLH group. Kaplan-Meier survival curves. (A) OS of non-SCT and SCT patients. (B) OS of non-SCT and SCT patients in AEBV-HLH group. (C) OS of non-SCT and SCT patients in CAEBV-HLH group. (D) OS of HLH-94/04 and DEP/LDEP regimen. For All EBV-HLH Patients As shown in Table 1 and Figure 4A, Univariate Cox regression analyses were conducted for factors associated with overall survival. Older (>60 years) patients (P=0.010) and male patients (P=0.028) suffered worse survival. The laboratory indicators including leukopenia (<4×109/L, P<0.001), thrombocytopenia (<100×109/L, P<0.001), anemia (<9 g/dL, P=0.002), elevated total bilirubin (TBIL) (>1.1 mg/dL, P=0.023), creatinine (>133 μmol/L, P<0.001), LDH (>ULN, P=0.032), ferritin (>5000 μg/L, P<0.001), sCD25 (>10000 U/mL, P<0.001), and decreased fibrinogen (<150 mg/dL, P=0.018) were associated with worse survival. Higher EBV‑DNA plasma load (>10000 copies/mL) was also associated with poor outcome (HR=1.51, P=0.004). Notably, patients with AEBV showed worse survival than those with CAEBV (HR=1.45, P=0.006). For treatment strategies, treatment with DEP/L‑DEP was associated with better survival (HR=0.79, P=0.049), and HSCT was a strong positive prognostic factor (HR=0.48, P<0.001).Table 1Univariate Cox Regression Analysis for Survival in All EBV-HLH PatientsVariablenHR95% CIP valueSex546FemaleRef.––Male1.291.03–1.610.028*Age (years)546≤60Ref.––>601.511.10–2.060.010*Fewer494NoRef.––Yes1.130.28–4.550.861Hepatomegaly441NoRef.––Yes1.080.86–1.370.512Splenomegaly464NoRef.––Yes1.370.98–1.910.066CNS symptom209NoRef.––Yes1.501.04–2.150.029*WBC (×109/L)448≥4Ref.––<41.651.21–2.230.001*ANC (×109/L)360≥1Ref.––<11.441.10–1.880.008*PLT (×109/L)458≥100Ref.––<1001.901.43–2.53<0.001**Hb (g/dL)425≥9Ref.––<91.471.15–1.880.002*CRP (mg/L)330≤10Ref.––>101.691.26–2.27<0.001**Creatinine (umol/L)363≤133Ref.––>1331.991.36–2.91<0.001**AST (U/L)402≤ULNRef.––>ULN1.210.90–1.620.204ALT (U/L)404≤ULNRef.––>ULN0.990.75–1.340.994TBIL (mg/dL)385≤1.1Ref.––>1.11.361.04–1.770.023*LDH (IU/L)414≤ULNRef.––>ULN1.771.05–3.000.032*TG (mg/dL)371<265Ref.––≥2651.150.88–1.500.317Ferritin (μg/L)433≤5000Ref.––>50002.081.41–3.07<0.001**sCD25 (U/mL)342≤10,000Ref.––>10,0001.971.43–2.72<0.001**sCD25/Ferritin341≤2Ref.––>21.100.80–1.510.557Fibrinogen (mg/dL)396≥150Ref.––<1501.351.05–1.740.018*Low NK cell activity276NoRef.––Yes1.010.75–1.360.938BM Hemophagocytosis433NoRef.––Yes1.120.84–1.500.444EBV load (copies/mL)362≤10000Ref.––>10,0001.511.13–2.02<0.004*AEBV546CAEBVRef.––AEBV1.451.11–1.890.006*DEP/L-DEP444NoRef.––Yes0.790.62–0.990.049*HSCT444NoRef.––Yes0.480.37–0.64<0.001**Note: *p<0.05. **p<0.001.Abbreviations: AEBV-HLH, acute Epstein-Barr virus infection associated hemophagocytic lymphohistiocytosis; Ref., reference; HR, hazard ratio; CI, confidence interval; CNS, central nervous system; WBC, white blood cell; ANC, absolute neutrophil count; Hb, hemoglobin; PLT, platelets; CRP, C-reactive protein; AST, aspartate transaminase; ULN, upper limit of normal; ALT, alanine transferase; TBIL, total bilirubin; LDH, lactate dehydrogenase; TG, triglyceride; sCD25, soluble CD25; NK, natural killer; BM, bone marrow; EBV, Epstein-Barr virus; AEBV, acute Epstein-Barr virus infection; CAEBV, chronic active Epstein–Barr virus infection; DEP/L-DEP, liposome doxorubicin, etoposide, methylprednisolone with or without asparaginase; HSCT, stem cell transplantation. Figure 4Unadjusted Cox regression analyses for overall survival in (A) entire cohort, (C) AEBV-HLH patients, and (E) CAEBV-HLH patients; multivariate-adjusted Cox regression analyses for overall survival in (B) entire cohort, (D) AEBV-HLH patients, and (F) CAEBV-HLH patients.Panels A, C, and E show unadjusted Cox regression analyses, and panels B, D, and F show multivariate-adjusted Cox regression analyses. In the overall cohort, higher sCD25, ferritin, and EBV load are associated with increased risk, and HSCT is associated with better survival in both unadjusted and adjusted models. In the AEBV-HLH group, sCD25, and EBV load remain significant risk factors and HSCT remains positive after adjustment. In the CAEBV-HLH group, HSCT is also associated with improved survival in the adjusted model, while sCD25/Ferritin and CNS symptom do not retain independent prognostic value after multivariate adjustment.Six forest plots showing unadjusted and multivariate-adjusted Cox regression analyses of overall survival in the entire cohort, AEBV-HLH patients, and CAEBV-HLH patients.Abbreviations: EBV, Epstein–Barr virus; AEBV-HLH, acute EBV-associated hemophagocytic lymphohistiocytosis; CAEBV-HLH, chronic active EBV-associated hemophagocytic lymphohistiocytosis; CI, confidence interval; CNS, central nervous system; HR, hazard ratio; HSCT, hematopoietic stem cell transplantation; sCD25, soluble CD25; TBIL, total bilirubin. Table 1Univariate Cox Regression Analysis for Survival in All EBV-HLH PatientsVariablenHR95% CIP valueSex546FemaleRef.––Male1.291.03–1.610.028*Age (years)546≤60Ref.––>601.511.10–2.060.010*Fewer494NoRef.––Yes1.130.28–4.550.861Hepatomegaly441NoRef.––Yes1.080.86–1.370.512Splenomegaly464NoRef.––Yes1.370.98–1.910.066CNS symptom209NoRef.––Yes1.501.04–2.150.029*WBC (×109/L)448≥4Ref.––<41.651.21–2.230.001*ANC (×109/L)360≥1Ref.––<11.441.10–1.880.008*PLT (×109/L)458≥100Ref.––<1001.901.43–2.53<0.001**Hb (g/dL)425≥9Ref.––<91.471.15–1.880.002*CRP (mg/L)330≤10Ref.––>101.691.26–2.27<0.001**Creatinine (umol/L)363≤133Ref.––>1331.991.36–2.91<0.001**AST (U/L)402≤ULNRef.––>ULN1.210.90–1.620.204ALT (U/L)404≤ULNRef.––>ULN0.990.75–1.340.994TBIL (mg/dL)385≤1.1Ref.––>1.11.361.04–1.770.023*LDH (IU/L)414≤ULNRef.––>ULN1.771.05–3.000.032*TG (mg/dL)371<265Ref.––≥2651.150.88–1.500.317Ferritin (μg/L)433≤5000Ref.––>50002.081.41–3.07<0.001**sCD25 (U/mL)342≤10,000Ref.––>10,0001.971.43–2.72<0.001**sCD25/Ferritin341≤2Ref.––>21.100.80–1.510.557Fibrinogen (mg/dL)396≥150Ref.––<1501.351.05–1.740.018*Low NK cell activity276NoRef.––Yes1.010.75–1.360.938BM Hemophagocytosis433NoRef.––Yes1.120.84–1.500.444EBV load (copies/mL)362≤10000Ref.––>10,0001.511.13–2.02<0.004*AEBV546CAEBVRef.––AEBV1.451.11–1.890.006*DEP/L-DEP444NoRef.––Yes0.790.62–0.990.049*HSCT444NoRef.––Yes0.480.37–0.64<0.001**Note: *p<0.05. **p<0.001.Abbreviations: AEBV-HLH, acute Epstein-Barr virus infection associated hemophagocytic lymphohistiocytosis; Ref., reference; HR, hazard ratio; CI, confidence interval; CNS, central nervous system; WBC, white blood cell; ANC, absolute neutrophil count; Hb, hemoglobin; PLT, platelets; CRP, C-reactive protein; AST, aspartate transaminase; ULN, upper limit of normal; ALT, alanine transferase; TBIL, total bilirubin; LDH, lactate dehydrogenase; TG, triglyceride; sCD25, soluble CD25; NK, natural killer; BM, bone marrow; EBV, Epstein-Barr virus; AEBV, acute Epstein-Barr virus infection; CAEBV, chronic active Epstein–Barr virus infection; DEP/L-DEP, liposome doxorubicin, etoposide, methylprednisolone with or without asparaginase; HSCT, stem cell transplantation. Univariate Cox Regression Analysis for Survival in All EBV-HLH Patients Note: *p<0.05. **p<0.001. Abbreviations: AEBV-HLH, acute Epstein-Barr virus infection associated hemophagocytic lymphohistiocytosis; Ref., reference; HR, hazard ratio; CI, confidence interval; CNS, central nervous system; WBC, white blood cell; ANC, absolute neutrophil count; Hb, hemoglobin; PLT, platelets; CRP, C-reactive protein; AST, aspartate transaminase; ULN, upper limit of normal; ALT, alanine transferase; TBIL, total bilirubin; LDH, lactate dehydrogenase; TG, triglyceride; sCD25, soluble CD25; NK, natural killer; BM, bone marrow; EBV, Epstein-Barr virus; AEBV, acute Epstein-Barr virus infection; CAEBV, chronic active Epstein–Barr virus infection; DEP/L-DEP, liposome doxorubicin, etoposide, methylprednisolone with or without asparaginase; HSCT, stem cell transplantation. Unadjusted Cox regression analyses for overall survival in (A) entire cohort, (C) AEBV-HLH patients, and (E) CAEBV-HLH patients; multivariate-adjusted Cox regression analyses for overall survival in (B) entire cohort, (D) AEBV-HLH patients, and (F) CAEBV-HLH patients. For 173 patients with sufficient data (no missing values for each variable), further multivariate analysis with a bidirectional stepwise selection procedure was performed to find the independent risk factors affecting the overall survival. Ferritin >5000 μg/L (P=0.044), sCD25 >10000 U/mL (P=0.009) and EBV-DNA load in plasma >10000 copies/mL (P=0.029) were identified as the independent risk factors. Unlike in univariate analyses, there was no difference between AEBV and CAEBV group (P=0.125). HSCT (P<0.001) remains as an independent positive prognostic factor for EBV-HLH patients (Figure 4B). For AEBV-HLH Subgroup Patients Univariate Cox regression was performed on 428 AEBV-HLH patients to identify potential prognostic factors. Male sex (HR=1.41, P=0.008), splenomegaly (HR=1.60, P=0.019), leukopenia (<4×109/L, HR=1.66, P=0.006), neutropenia (<1×109/L, HR=1.42, P=0.018), thrombocytopenia (<100×109/L, HR=1.99, P<0.001), anemia (<9 g/dL, HR=1.43, P=0.010), CRP >10 mg/L (HR=1.94, P<0.001), creatinine >133 μmol/L (HR=1.95, P<0.001), TBIL >1.1 mg/dL (HR=1.38, P=0.032), elevated LDH (HR=1.44, P=0.012), sCD25 >10000 U/mL (HR=1.88, P<0.001), and EBV-DNA load >10000 copies/mL (HR=1.56, P=0.008) were associated with worse prognosis. Treatment with HSCT was a strong protective factor (HR=0.57, P<0.001). DEP/L-DEP treatment was not significantly associated with survival. All results are summarized in Table 2 and Figure 4C.Table 2Univariate Cox Regression Analysis for Survival in AEBV-HLH PatientsVariablenHR95% CIP valueSex428FemaleRef.––Male1.411.10–1.780.008*Age (years)428≤60Ref.––>601.250.88–1.780.215Fewer383NoRef.––Yes1.240.31–5.010.759Hepatomegaly349NoRef.––Yes1.110.85–1.450.453Splenomegaly372NoRef.––Yes1.61.08–2.380.019*CNS symptom157NoRef.––Yes1.310.84–2.030.229WBC (×109/L)353≥4Ref.––<41.661.16–2.380.006*ANC (×109/L)287≥1Ref.––<11.421.06–1.900.018*PLT (×109/L)359≥100Ref.––<1001.991.43–2.77<0.001**Hb (g/dL)333≥9Ref.––<91.431.09–1.880.010*CRP (mg/L)260≤10Ref.––>101.941.40–2.68<0.001**Creatinine (umol/L)288≤133Ref.––>1331.951.30–2.93<0.001**AST (U/L)316≤ULNRef.––>ULN1.290.92–1.810.141ALT (U/L)318≤ULNRef.––>ULN0.970.69–1.350.848TBIL (mg/dL)304≤1.1Ref.––>1.11.381.03–1.850.032*LDH (IU/L)330≤ULNRef.––>ULN1.441.08–1.910.012*TG (mg/dL)296<265Ref.––≥2651.150.86–1.550.340Ferritin (μg/L)339≤5000Ref.––>50001.310.99–1.720.055sCD25 (U/mL)269≤10,000Ref.––>10,0001.881.30–2.720.001*sCD25/Ferritin268≤2Ref.––>20.960.68–1.340.791Fibrinogen (mg/dL)314≥150Ref.––<1501.290.98–1.700.075Low NK cell activity220NoRef.––Yes0.970.70–1.350.878BM Hemophagocytosis342NoRef.––Yes1.120.80–1.560.523EBV load (copies/mL)278≤10,000Ref.––>10,0001.561.12–2.170.008*DEP/L-DEP340NoRef.––Yes0.860.65–1.130.269HSCT340NoRef.––Yes0.570.41–0.79<0.001**Note: *p<0.05. **p<0.001.Abbreviations: AEBV-HLH, acute Epstein-Barr virus infection associated hemophagocytic lymphohistiocytosis; Ref., reference; HR, hazard ratio; CI, confidence interval; CNS, central nervous system; WBC, white blood cell; ANC, absolute neutrophil count; Hb, hemoglobin; PLT, platelets; CRP, C-reactive protein; AST, aspartate transaminase; ULN, upper limit of normal; ALT, alanine transferase; TBIL, total bilirubin; LDH, lactate dehydrogenase; TG, triglyceride; sCD25, soluble CD25; NK, natural killer; BM, bone marrow; EBV, Epstein-Barr virus; DEP/L-DEP, liposome doxorubicin, etoposide, methylprednisolone with or without asparaginase; HSCT, stem cell transplantation. Table 2Univariate Cox Regression Analysis for Survival in AEBV-HLH PatientsVariablenHR95% CIP valueSex428FemaleRef.––Male1.411.10–1.780.008*Age (years)428≤60Ref.––>601.250.88–1.780.215Fewer383NoRef.––Yes1.240.31–5.010.759Hepatomegaly349NoRef.––Yes1.110.85–1.450.453Splenomegaly372NoRef.––Yes1.61.08–2.380.019*CNS symptom157NoRef.––Yes1.310.84–2.030.229WBC (×109/L)353≥4Ref.––<41.661.16–2.380.006*ANC (×109/L)287≥1Ref.––<11.421.06–1.900.018*PLT (×109/L)359≥100Ref.––<1001.991.43–2.77<0.001**Hb (g/dL)333≥9Ref.––<91.431.09–1.880.010*CRP (mg/L)260≤10Ref.––>101.941.40–2.68<0.001**Creatinine (umol/L)288≤133Ref.––>1331.951.30–2.93<0.001**AST (U/L)316≤ULNRef.––>ULN1.290.92–1.810.141ALT (U/L)318≤ULNRef.––>ULN0.970.69–1.350.848TBIL (mg/dL)304≤1.1Ref.––>1.11.381.03–1.850.032*LDH (IU/L)330≤ULNRef.––>ULN1.441.08–1.910.012*TG (mg/dL)296<265Ref.––≥2651.150.86–1.550.340Ferritin (μg/L)339≤5000Ref.––>50001.310.99–1.720.055sCD25 (U/mL)269≤10,000Ref.––>10,0001.881.30–2.720.001*sCD25/Ferritin268≤2Ref.––>20.960.68–1.340.791Fibrinogen (mg/dL)314≥150Ref.––<1501.290.98–1.700.075Low NK cell activity220NoRef.––Yes0.970.70–1.350.878BM Hemophagocytosis342NoRef.––Yes1.120.80–1.560.523EBV load (copies/mL)278≤10,000Ref.––>10,0001.561.12–2.170.008*DEP/L-DEP340NoRef.––Yes0.860.65–1.130.269HSCT340NoRef.––Yes0.570.41–0.79<0.001**Note: *p<0.05. **p<0.001.Abbreviations: AEBV-HLH, acute Epstein-Barr virus infection associated hemophagocytic lymphohistiocytosis; Ref., reference; HR, hazard ratio; CI, confidence interval; CNS, central nervous system; WBC, white blood cell; ANC, absolute neutrophil count; Hb, hemoglobin; PLT, platelets; CRP, C-reactive protein; AST, aspartate transaminase; ULN, upper limit of normal; ALT, alanine transferase; TBIL, total bilirubin; LDH, lactate dehydrogenase; TG, triglyceride; sCD25, soluble CD25; NK, natural killer; BM, bone marrow; EBV, Epstein-Barr virus; DEP/L-DEP, liposome doxorubicin, etoposide, methylprednisolone with or without asparaginase; HSCT, stem cell transplantation. Univariate Cox Regression Analysis for Survival in AEBV-HLH Patients Note: *p<0.05. **p<0.001. Abbreviations: AEBV-HLH, acute Epstein-Barr virus infection associated hemophagocytic lymphohistiocytosis; Ref., reference; HR, hazard ratio; CI, confidence interval; CNS, central nervous system; WBC, white blood cell; ANC, absolute neutrophil count; Hb, hemoglobin; PLT, platelets; CRP, C-reactive protein; AST, aspartate transaminase; ULN, upper limit of normal; ALT, alanine transferase; TBIL, total bilirubin; LDH, lactate dehydrogenase; TG, triglyceride; sCD25, soluble CD25; NK, natural killer; BM, bone marrow; EBV, Epstein-Barr virus; DEP/L-DEP, liposome doxorubicin, etoposide, methylprednisolone with or without asparaginase; HSCT, stem cell transplantation. Multivariate Cox regression analysis revealed that sCD25 >10000 U/mL (HR=2.08, P=0.019) and EBV-DNA load >10000 copies/mL (HR=1.86, P=0.011) were independent risk factors for worse survival. Notably, HSCT remained a strong independent protective factor (HR=0.39, P<0.001) (Figure 4D). For CAEBV-HLH Subgroup Patients In CAEBV-HLH patients, univariate Cox regression was conducted on 118 CAEBV patients. Age >60 years (HR=3.21, P<0.001), CNS symptoms (HR=3.27, P=0.005), and an elevated sCD25/Ferritin ratio (>2, HR=3.65, P=0.031) were identified as significant risk factors for poor prognosis. In terms of treatment, DEP/L-DEP therapy was associated with improved survival (HR=0.58, P=0.033), and HSCT remained a protective factor (HR=0.34, P<0.001). Conversely, EBV load did not show a significant association with survival in this subgroup (Table 3 and Figure 4E).Table 3Univariate Cox Regression Analysis for Survival in CAEBV-HLH PatientsVariablenHR95% CIP valueSex118FemaleRef.––Male0.970.60–1.560.897Age (years)108≤60Ref.––>603.211.63–6.34<0.001**Hepatomegaly108NoRef.––Yes1.090.67–1.800.722Splenomegaly108NoRef.––Yes0.800.43–1.510.494CNS symptom52NoRef.––Yes3.271.44–7.430.005*WBC (×109/L)95≥4Ref.––<41.420.78–2.580.254ANC (×109/L)73≥1Ref.––<11.190.60–2.370.615PLT (×109/L)99≥100Ref.––<1001.560.88–2.760.126Hb (g/dL)92≥9Ref.––<91.470.85–2.540.170CRP (mg/L)70≤10Ref.––>101.030.53–2.040.922Creatinine (μmol/L)75≤133Ref.––>1331.840.65–5.200.248AST (U/L)90≤ULNRef.––>ULN0.960.52–1.750.887ALT (U/L)90≤ULNRef.––>ULN1.040.56–1.950.895TBIL (mg/dL)81≤1.1Ref.––>1.11.110.59–2.070.747LDH (IU/L)84≤ULNRef.––>ULN0.840.47–1.520.570TG (mg/dL)78<265Ref.––≥2650.950.49–1.850.888Ferritin (μg/L)94≤5000Ref.––>50001.040.58–1.880.884sCD25 (U/mL)73≤10000Ref.––>10,0001.900.97–3.710.060sCD25/Ferritin73≤2Ref.––>23.651.12–11.860.031*Low NK cell activity56NoRef.––Yes1.390.67–2.910.376Fibrinogen (mg/dL)82≥150Ref.––<1501.500.83–2.720.183BM Hemophagocytosis91NoRef.––Yes0.990.54–1.810.975EBV load (copies/mL)84≤10000Ref.––>10,0001.330.73–2.440.348DEP/L-DEP104NoRef.––Yes0.580.35–0.960.033*HSCT104NoRef.––Yes0.340.19–0.59<0.001**Note: *p<0.05. **p<0.001.Abbreviations: CAEBV-HLH, chronic active Epstein–Barr virus infection associated hemophagocytic lymphohistiocytosis; Ref., reference; HR, hazard ratio; CI, confidence interval; CNS, central nervous system; WBC, white blood cell; ANC, absolute neutrophil count; Hb, hemoglobin; PLT, platelets; CRP, C-reactive protein; AST, aspartate transaminase; ULN, upper limit of normal; ALT, alanine transferase; TBIL, total bilirubin; LDH, lactate dehydrogenase; TG, triglyceride; sCD25, soluble CD25; NK, natural killer; BM, bone marrow; EBV, Epstein-Barr virus; DEP/L-DEP, liposome doxorubicin, etoposide, methylprednisolone with or without asparaginase; HSCT, stem cell transplantation. Table 3Univariate Cox Regression Analysis for Survival in CAEBV-HLH PatientsVariablenHR95% CIP valueSex118FemaleRef.––Male0.970.60–1.560.897Age (years)108≤60Ref.––>603.211.63–6.34<0.001**Hepatomegaly108NoRef.––Yes1.090.67–1.800.722Splenomegaly108NoRef.––Yes0.800.43–1.510.494CNS symptom52NoRef.––Yes3.271.44–7.430.005*WBC (×109/L)95≥4Ref.––<41.420.78–2.580.254ANC (×109/L)73≥1Ref.––<11.190.60–2.370.615PLT (×109/L)99≥100Ref.––<1001.560.88–2.760.126Hb (g/dL)92≥9Ref.––<91.470.85–2.540.170CRP (mg/L)70≤10Ref.––>101.030.53–2.040.922Creatinine (μmol/L)75≤133Ref.––>1331.840.65–5.200.248AST (U/L)90≤ULNRef.––>ULN0.960.52–1.750.887ALT (U/L)90≤ULNRef.––>ULN1.040.56–1.950.895TBIL (mg/dL)81≤1.1Ref.––>1.11.110.59–2.070.747LDH (IU/L)84≤ULNRef.––>ULN0.840.47–1.520.570TG (mg/dL)78<265Ref.––≥2650.950.49–1.850.888Ferritin (μg/L)94≤5000Ref.––>50001.040.58–1.880.884sCD25 (U/mL)73≤10000Ref.––>10,0001.900.97–3.710.060sCD25/Ferritin73≤2Ref.––>23.651.12–11.860.031*Low NK cell activity56NoRef.––Yes1.390.67–2.910.376Fibrinogen (mg/dL)82≥150Ref.––<1501.500.83–2.720.183BM Hemophagocytosis91NoRef.––Yes0.990.54–1.810.975EBV load (copies/mL)84≤10000Ref.––>10,0001.330.73–2.440.348DEP/L-DEP104NoRef.––Yes0.580.35–0.960.033*HSCT104NoRef.––Yes0.340.19–0.59<0.001**Note: *p<0.05. **p<0.001.Abbreviations: CAEBV-HLH, chronic active Epstein–Barr virus infection associated hemophagocytic lymphohistiocytosis; Ref., reference; HR, hazard ratio; CI, confidence interval; CNS, central nervous system; WBC, white blood cell; ANC, absolute neutrophil count; Hb, hemoglobin; PLT, platelets; CRP, C-reactive protein; AST, aspartate transaminase; ULN, upper limit of normal; ALT, alanine transferase; TBIL, total bilirubin; LDH, lactate dehydrogenase; TG, triglyceride; sCD25, soluble CD25; NK, natural killer; BM, bone marrow; EBV, Epstein-Barr virus; DEP/L-DEP, liposome doxorubicin, etoposide, methylprednisolone with or without asparaginase; HSCT, stem cell transplantation. Univariate Cox Regression Analysis for Survival in CAEBV-HLH Patients Note: *p<0.05. **p<0.001. Abbreviations: CAEBV-HLH, chronic active Epstein–Barr virus infection associated hemophagocytic lymphohistiocytosis; Ref., reference; HR, hazard ratio; CI, confidence interval; CNS, central nervous system; WBC, white blood cell; ANC, absolute neutrophil count; Hb, hemoglobin; PLT, platelets; CRP, C-reactive protein; AST, aspartate transaminase; ULN, upper limit of normal; ALT, alanine transferase; TBIL, total bilirubin; LDH, lactate dehydrogenase; TG, triglyceride; sCD25, soluble CD25; NK, natural killer; BM, bone marrow; EBV, Epstein-Barr virus; DEP/L-DEP, liposome doxorubicin, etoposide, methylprednisolone with or without asparaginase; HSCT, stem cell transplantation. To determine the independent prognostic factors in CAEBV-HLH patients, a multivariate Cox regression model was constructed. The analysis revealed that receiving HSCT was the only independent protective factor (HR=0.25, P=0.017). While the presence of CNS symptoms (HR = 2.29, P = 0.141) and an elevated sCD25/Ferritin (>2, HR = 3.22, P = 0.138) were associated with higher estimated mortality, these associations did not reach statistical significance in the multivariate analysis (Figure 4F). Discussions EBV is a ubiquitous pathogen with near-universal human susceptibility, leading asymptomatic infections in approximately 90% of cases.11 Infection of EBV in T cells and NK cells leads to large-scale expansion and activation of infected cells. Continuous antigen stimulation causes uncontrolled proliferation and activation of T cells and NK cells, producing excessive interferon and stimulating macrophage secretion, causing a storm of inflammatory factors. HLH is a severe, life-threatening hyperinflammatory syndrome. EBV-HLH refers to HLH triggered by EBV infection, which is recognized as the most prevalent infectious association with HLH. A US study associated EBV infection with HLH in about 1/3 of HLH patients,12 while Chinese and Japanese data confirmed EBV infection in 75% and 54% of infection-associated HLH cases, respectively.13,14 In our research cohort, Asian patients constituted the majority, which is consistent with epidemiological results of previous studies. Baseline data showed that HLH-related indicators in the AEBV-HLH group were worse than those in the CAEBV-HLH group, including WBC, PLT, LDH, ferritin, TG, and EBV load. This may suggest that HLH secondary to AEBV exhibits a more acute process of HLH driven by infection of EBV. In multivariate analysis, baseline indicators in AEBV showed a more prominent impact. Univariate analysis revealed that acute cytopenias including leukopenia, neutropenia, thrombocytopenia, and anemia were strongly associated with adverse survival outcomes, which represent active EBV-driven hemophagocytosis. Concurrently, systemic inflammatory markers including elevated CRP, TBIL, and LDH emerged as significant risk factors, underscoring the role of acute systemic inflammation in driving mortality. Of clinical significance, elevated sCD25 (>10000 U/mL) and high EBV-DNA load in plasma (>10000 copies/mL) persisted as independent prognostic factors in multivariate regression, confirming their utility as biomarkers for risk assessment in AEBV-HLH patients. These findings emphasize that AEBV-HLH pathology is characterized by acute, active disease processes, and thus therapeutic interventions should focus on rapidly controlling systemic inflammation and viral replication. By contrast, CNS symptoms were more common in CAEBV-HLH than AEBV-HLH, which may be attributed to the chronic disease process being more likely to involve the CNS. Advanced age, CNS symptoms, and an elevated sCD25/Ferritin ratio were the only risk factors identified by univariate analysis in CAEBV-HLH patients. The sCD25/Ferritin ratio has been reported to be significantly higher in lymphoma-associated HLH than in HLH secondary to benign diseases.15 This suggests that CAEBV, representing a chronic and indolent condition, is driven more by long-term disease burden and complications rather than acute inflammation. The persistent EBV infection in CAEBV-HLH patients leads to the sustained activation of HLH. At present, HSCT is the only effective treatment to eradicate EBV-infected cells in CAEBV,16 while controversy persists regarding its application in AEBV-HLH due to the risk of transplant-related mortality. Notably, a prior meta-analysis focused on pediatric HLH failed to demonstrate the superiority of HSCT over etoposide-containing immunochemotherapy.17 However, our study focused on adult patients and found AEBV-HLH patients had significantly shorter median survival compared with the CAEBV-HLH group. We attribute this outcome to the more rapid disease progression in AEBV-HLH, resulting in fewer patients being eligible for HSCT, leading to poorer survival. This is further supported by the notably higher transplantation rate observed in the CAEBV-HLH group in our study. Both univariate and multivariate analyses supported the survival benefit of HSCT. These findings suggest potential therapeutic advantages of HSCT for AEBV patients, though incomplete data precluded assessment of whether early HSCT could further improve long-term outcome. Rebuilding the immune system through HSCT is a reliable method to prevent sustained virus replication and provide long-term benefit. Therefore, there is a critical need for standardized, prospective global registries of adult patients to determine the optimal timing of HSCT. In recent years, chimeric antigen receptor-T cell therapy (CAR-T) therapy has been explored for chronic infectious diseases.18 For EBV, several studies have shown that CAR-T cells targeting EBV antigens, such as latent membrane protein 1 (LMP1)19 and glycoprotein 350 (gp350),20 can effectively control the progression of EBV-associated malignancies in vitro and in animal models. Similar to the use of HSCT to eliminate EBV infection in EBV-HLH, CAR-T therapies targeting EBV may help eradicate the underlying EBV infection and could have potential therapeutic value in EBV-HLH, although further investigation is still needed. Regarding bridging therapy to transplantation, we also demonstrated DEP/LDEP regimen was associated with a superior 30‑day survival rate compared with the HLH‑94/04 regimen. Patients receiving DEP/LDEP followed by HSCT had better long‑term survival than those by HLH‑94/04. No survival difference was seen between these two regimens among patients without HSCT. In multivariate analysis, only HSCT was identified as an independent prognostic factor. Consistent with previous studies,21,22 DEP/LDEP regimens provide better early survival than HLH-94/04, serving as an effective bridge to HSCT rather than a curative treatment, though only HSCT improves long-term survival. In the overall cohort and the AEBV subgroup, EBV load was an independent risk factor for mortality. The replication and reactivation of EBV are associated with HLH prognosis.23 In adult EBV-HLH, high levels of EBV-DNA loading are significantly associated with worse therapy response and poorer outcomes.24 Adult patients with excessive EBV-DNA load were more likely to relapse and should prompt an approach with aggressive therapeutic interventions.25 The quantification of EBV-DNA load has been widely recognized as a valuable biomarker in EBV-associated diseases. EBV-DNA in plasma mainly comes from apoptotic or necrotic cells. Patients with high levels of peripheral blood mononuclear cells (PBMC) EBV-DNA and plasma EBV-DNA before treatment and those with repeated elevation of plasma EBV-DNA during treatment have a poorer prognosis.26 Elevated plasma EBV-DNA load has been identified as a potential predictive marker for the transition from CAEBV to HLH.27 Therefore, EBV load can be used as a biomarker to assess disease severity or patient prognosis.28 Our study confirmed that elevated EBV-DNA loads in plasma, especially over 10000 copies/mL, predicted poorer survival in EBV-HLH patients through univariate and multivariate analysis, demonstrating its prognostic value for disease severity and outcomes. In our study, we found plasma EBV loads were higher in AEBV group than CAEBV group. The reason might be that AEBV-HLH typically presents as an acute condition with widespread viral replication, leading to a higher EBV-DNA load in plasma. In CAEBV-HLH, the immune system cannot effectively control the long-term presence and reactivation of the virus, causing higher viral loads in PBMC, even though plasma levels are lower.29 Plasma EBV-DNA shows better prognostic performance than PBMC viral load in pediatric patients,30 highlighting the importance of EBV-DNA monitoring in adults. This study has several limitations. The retrospective design and reliance on published individual patient data limited the availability of complete clinical information, which restricted some analyses and may have affected the reliability of the model. In addition, publication bias cannot be ruled out, as cases with distinctive or notable features may be more likely to be reported. Despite these restrictions, this comprehensive scoping review provides overview of clinical characteristics, epidemiology, treatment, and prognostic profile. This study provides supportive evidence that EBV-HLH is a distinct disease, both in terms of clinical manifestations and prognostic influencing factors. Our analyses identify distinct prognostic and therapeutic differences between the AEBV-HLH and CAEBV-HLH subtypes. AEBV is characterized by acute inflammatory and infection requiring urgent control, whereas CAEBV displays a chronic progress driven by persistent viral infection and long‑term organ complications. Such differences in disease status lead to distinct prognostic factors. Notably, HSCT remains the only strong and independent factor associated with improved long‑term survival across both subtypes. Overall, our findings provide evidence to support clinical management and prognostic assessment in adult EBV-HLH, and highlight the need for future prospective, multicenter studies to validate. In addition, mechanistic studies are needed to better understand AEBV-HLH and CAEBV-HLH to support the implementation of strategies in different subtypes and underscoring the central role of HSCT in treatment.